$18.60—Stale · unknown old
NYSE • Last print unknown ago
$18.60—Stale · unknown old
The KraneShares MSCI All China Health Care Index ETF (KURE) focuses on providing exposure to the Chinese healthcare sector, including pharmaceuticals, biotechnology, and healthcare equipment. Its competitive position is bolstered by a unique focus on the rapidly growing Chinese healthcare market, driven by demographic trends and increasing healthcare spending.
KURE generates revenue primarily through management fees based on the total assets under management. Its competitive advantage lies in its specialized focus on the Chinese healthcare sector, which is expected to grow significantly due to an aging population and rising health expenditures.
Changes in healthcare policy in China, such as drug pricing reforms
Fluctuations in the performance of underlying healthcare stocks in China
Investor sentiment towards emerging markets, particularly China
Changes in global healthcare trends impacting demand for Chinese healthcare products
Regulatory changes in China's healthcare sector that could impact profitability
Technological disruption in healthcare delivery and pharmaceuticals
Increased competition from other ETFs focusing on Chinese healthcare or broader emerging markets
Potential for market saturation as more funds enter the space
Low liquidity risk due to the nature of ETF structures
Market risk associated with the volatility of underlying equities
high - The performance of KURE is closely linked to GDP growth in China, which influences healthcare spending.
Rising interest rates may lead to higher financing costs for healthcare companies, potentially impacting their stock prices and, consequently, KURE's performance.
minimal
growth - Investors seeking exposure to high-growth sectors in emerging markets, particularly healthcare.
moderate - The ETF's volatility is influenced by the underlying stocks, which can be more volatile than developed markets.